Clover Health Investments Statistics
Total Valuation
CLOV has a market cap or net worth of $1.39 billion. The enterprise value is $1.24 billion.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLOV has 508.92 million shares outstanding. The number of shares has increased by 1.78% in one year.
| Current Share Class | 416.54M |
| Shares Outstanding | 508.92M |
| Shares Change (YoY) | +1.78% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 22.32% |
| Owned by Institutions (%) | 21.20% |
| Float | 393.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.24 |
| PS Ratio | 0.91 |
| Forward PS | 0.69 |
| PB Ratio | 4.13 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54
| Current Ratio | 1.54 |
| Quick Ratio | 1.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -7.75% and return on invested capital (ROIC) is -4.82%.
| Return on Equity (ROE) | -7.75% |
| Return on Assets (ROA) | -2.43% |
| Return on Invested Capital (ROIC) | -4.82% |
| Return on Capital Employed (ROCE) | -6.63% |
| Revenue Per Employee | $2.61M |
| Profits Per Employee | -$44,058 |
| Employee Count | 570 |
| Asset Turnover | 2.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +115.75% in the last 52 weeks. The beta is 1.93, so CLOV's price volatility has been higher than the market average.
| Beta (5Y) | 1.93 |
| 52-Week Price Change | +115.75% |
| 50-Day Moving Average | 3.28 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 32.94 |
| Average Volume (20 Days) | 6,327,990 |
Short Selling Information
The latest short interest is 20.44 million, so 4.02% of the outstanding shares have been sold short.
| Short Interest | 20.44M |
| Short Previous Month | 15.58M |
| Short % of Shares Out | 4.02% |
| Short % of Float | 5.20% |
| Short Ratio (days to cover) | 3.19 |
Income Statement
In the last 12 months, CLOV had revenue of $1.49 billion and -$25.11 million in losses. Loss per share was -$0.05.
| Revenue | 1.49B |
| Gross Profit | 391.93M |
| Operating Income | -24.39M |
| Pretax Income | -123.70M |
| Net Income | -25.11M |
| EBITDA | -22.91M |
| EBIT | -24.39M |
| Loss Per Share | -$0.05 |
Full Income StatementBalance Sheet
The company has $160.10 million in cash and n/a in debt, giving a net cash position of $155.44 million or $0.31 per share.
| Cash & Cash Equivalents | 160.10M |
| Total Debt | n/a |
| Net Cash | 155.44M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 336.08M |
| Book Value Per Share | 0.66 |
| Working Capital | 115.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.38 million and capital expenditures -$1.30 million, giving a free cash flow of -$8.68 million.
| Operating Cash Flow | -7.38M |
| Capital Expenditures | -1.30M |
| Free Cash Flow | -8.68M |
| FCF Per Share | -$0.02 |
Full Cash Flow StatementMargins
Gross margin is 26.37%, with operating and profit margins of -1.64% and -1.69%.
| Gross Margin | 26.37% |
| Operating Margin | -1.64% |
| Pretax Margin | -1.64% |
| Profit Margin | -1.69% |
| EBITDA Margin | -1.54% |
| EBIT Margin | -1.64% |
| FCF Margin | n/a |
Dividends & Yields
CLOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.78% |
| Shareholder Yield | -1.78% |
| Earnings Yield | -1.80% |
| FCF Yield | -0.62% |
Dividend DetailsAnalyst Forecast
The average price target for CLOV is $4.83, which is 76.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.83 |
| Price Target Difference | 76.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 17.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
